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Abstract
Background: Q fever has become a major public health problem in the Netherlands. Infection with Coxiella
burnetii (Q fever) during pregnancy has resulted in adverse pregnancy outcome in the majority of reported cases.
Therefore, we aimed to quantify this risk by examining the earliest periods corresponding to the epidemic in the
Netherlands.
Methods: Serum samples that had been collected from the area of highest incidence by an existing national
prenatal screening programme and data from the Netherlands Perinatal Registry (PRN) on diagnosis and outcome
were used. We performed indirect immunofluorescence assay to detect the presence of IgM and IgG antibodies
against C. burnetii in the samples. The serological results were analyzed to determine statistical association with
recorded pregnancy outcome.
Results: Evaluation of serological results for 1174 women in the PRN indicated that the presence of IgM and IgG
antibodies against phase II of C. burnetii was not significantly associated with preterm delivery, low birth weight, or
several other outcome measures.
Conclusion: The present population-based study showed no evidence of adverse pregnancy outcome among
women who had antibodies to C. burnetii during early pregnancy.
Background
Infection with Coxiella burnetii (Q fever) has recently
become a major public health problem in the Netherlands
[1,2]. The annual number of laboratory-confirmed cases
increased from 10 in 2006 to 168 in 2007. Since then, the
upward trend has continued at an alarming rate (weekly
updates on number of cases is available in Dutch at:
http://www.rivm.nl/cib/themas/Q-koorts/). The 2008 out-
break, comprised of 1000 cases, was ranked as the largest
on record anywhere in the world, but this was surpassed
in 2009 when a total of 2356 cases were diagnosed.
International literature suggests that untreated acute
Q fever infection during pregnancy may result in
adverse pregnancy outcome in up to 81% of cases [3,4].
These outcomes include spontaneous abortion, intra-
uterine foetal death and premature delivery, or low birth
weight. The risk of developing chronic Q fever infection
is especially high for pregnant women [5-7]. An esti-
mated 60% of all (male and female) acute Q fever infec-
tions occur without clinical symptoms, and among
pregnant women this percentage is even higher [8].
Asymptomatic infections may carry the same risk for
adverse pregnancy outcome as symptomatic cases [9].
The high proportion of asymptomatic infections and the
high risk for adverse effects has led to recommendations
which state that in outbreak situations all pregnant
women should be offered serological screening for
recent Q fever infection; if found positive, long-term
antibiotic treatment is proposed [8]. During the first
outbreak in the Netherlands in 2007 an effort was made
to identify all women who were pregnant or who had
recently delivered in the affected area (total approximate
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through midwives and obstetricians serving the area, 19
underwent serological testing with an indirect immuno-
fluorescence assay (IFA). None of these women pre-
sented with symptoms of Q fever, but serological
evidence of a recent infection was found for two and for
a past infection in one other [10]. As recommended in
the international literature, the two women with recent
infection were treated with cotrimoxazole for the dura-
tion of their pregnancies [4]. These two women deliv-
ered under strict hygiene measures and there were no
complications during parturition. PCR tests of birth pro-
ducts were negative for C. burnetii DNA.
The number of pregnant women with Q fever infection
for whom pregnancy outcome has been reported is very
limited (<100 women for all studies combined). Further-
more, most studies have been based upon retrospectively
collected cases that do not allow quantification of the
r i s kf o ra na d v e r s eo u t c o m eo fa ni n f e c t i o nd u r i n gp r e g -
nancy. The 2008 outbreak in the Netherlands was unique
from those that had preceded it in that it was not con-
fined to a small geographic area; this widespread infec-
tion pattern raised the question of whether screening of
pregnant women for acute Q fever infection was neces-
sary and feasible. The answer is largely dependent on the
trade-off between adverse effects from untreated Q fever
infections and the detrimental side effects associated with
long-term antibiotic treatment during pregnancy.
Furthermore, it will be necessary to minimize the poten-
tial for administering an unnecessary treatment based on
a false positive serological result.
An international meeting conducted in July 2008 by
t h eC e n t r ef o rI n f e c t i o u sD i s e a s eC o n t r o la n dt h e
Health Council of the Netherlands concluded that, con-
sidering the prevailing conditions in which cases were
emerging over a large geographic area, screening of all
pregnant women for recent Q fever infection was not
justified but that there was an urgent need for more
quantitative data to determine the risk of adverse preg-
nancy outcome among pregnant women with acute Q
fever infection in early pregnancy. The findings would
then be provided to health planners and policy makers
in order to aid in the development of targeted and effec-
tive programmes of countermeasures (available in Dutch
at: http://www.gezondheidsraad.nl/nl/adviezen/briefad-
vies-bijeenkomst-over-q-koorts-nederland). To this end,
we designed and carried out a population-based retro-
spective follow-up study of pregnant women in the
Netherlands region with highest incidence of Q fever.
Methods
Serology
Presence of antibodies against C. burnetii during preg-
nancy was determined by testing sera that had been
routinely collected by the Prenatal Screening for Infec-
tious Diseases and Erythrocyte Immunization (PSIE).
This is a screening program that is offered free-of-
charge to all pregnant women in the Netherlands
around the 12
th week of pregnancy. It includes screening
for hepatitis B, syphilis, and HIV. Participation in the
PSIE is voluntary and reaches around 93%. Under this
program, the midwife refers the pregnant woman for
collection of a blood sample to occur during a regular
antenatal care visit. Samples collected under the PSIE
can be analyzed at any microbiology laboratory and the
remaining serum is often stored for a period of one year
after initial analysis.
We obtained the stored sera from regional laboratories
located in the northeast of the province of Noord Bra-
bant, which represented the area with the highest Q
fever incidence. These sera had been stored in freezers
at -20°C after analysis for hepatitis B, syphilis, and HIV.
Sera with collection dates from 20 June 2007 to 31 July
2008 were sent on dry ice to the Regional Laboratory of
Medical Microbiology and Infection Control in the Jer-
oen Bosch Hospital located in ‘s Hertogenbosch, where
they were kept in the freezer at -20°C. When a batch of
sera was removed from the freezer and thawed, they
were analysed the same day for Q fever serology using
an IFA device (Focus Diagnostics, Cypress, CA, USA) to
detect the presence of IgG and IgM antibodies. In the
analysis the positive serological results were categorised
in two categories: (1) the presence of anti-phase II IgM
and anti-phase II IgG antibodies with a titre of ≥1:64 or
as o l i t a r yI g MI I≥1:64, suggesting a possible recent
infection; and (2) the presence of both anti-phase I and
II IgG antibodies with a titre of ≥1:64 and without IgM
being present, suggesting a past infection. The remain-
ing samples were scored as negative for C. burnetii
infection.
Pregnancy outcome
Information on pregnancy outcome for each of the sam-
ples was obtained from the Netherlands Perinatal Regis-
try (PRN). This database represents the joint efforts of
the professional organizations of midwives, gynaecolo-
gists, obstetrically-trained general practitioners and pae-
diatricians in the Netherlands. The PRN contains
perinatal data from 16 weeks of gestation onwards and
includes 96% of all births that occur in the Netherlands
(http://www.perinatreg.nl/).
A number of outcome variables were assessed in our
study: (1) preterm delivery, defined as gestational age
under 37 weeks; (2) low birth weight, defined as <2500
grams; (3) low birth weight for gestational age, defined
as <10
th percentile, derived from sex-, parity, and ethnic
background-specific reference curves [11]; (4) foetal or
neonatal mortality, up to 7 days (5) congenital
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5-minute Apgar score <7.
Confounding variables
Information was also collected on a number of poten-
tially confounding variables known to be associated with
pregnancy outcome and for which information was
available in the PRN. These included maternal age, par-
ity, plurality, ethnic background, socio-economic status,
urbanization, and foetal position. Socio-economic status
was estimated from the woman’s postal code (4 digits)
using the methodology developed by the Netherlands
Institute for Social Research [12]. The socio-economic
status is based on mean income level, the percentage of
households with a low income, the percentage of inhabi-
tants without a paid job and the percentage of house-
holds with, on average, a low education residing within
a particular postal code area. Ethnic background was
classified by the healthcare provider as Dutch or other
(largely consisting of ethnic groups from Surinam, Mor-
occo, and Turkey). Urbanization was based on the num-
ber of households per km
2 per postal code area.
Sample size calculation
It was assumed that the prevalence of antibodies against
C. burnetii among pregnant women in the high-risk
area would be around 10%. This presumption was based
on a limited seroprevalence survey among pregnant
women during the 2007 outbreak, which showed recent
infection in 16% in the outbreak area, 4% in the sur-
rounding ‘medium risk’ area, and 1% in the rest of the
country [10]. The proportion of newborns with low
birth weight (<2500 grams) has been reported to be
about 7% in the Netherlands [13]. With this outcome
measure, the required sample size to detect a relative
risk of two with a power of 80% and a significance level
of 5% would be 1630. A slightly smaller sample size
would be required for the outcome measure preterm
delivery (gestational age <37 weeks), which occurs in 8%
of pregnancies. From the outset, this study was expected
to have insufficient power to detect an increased risk in
foetal and neonatal mortality (perinatal mortality) due to
the fact this is a rare event which occurs in only about
1% of pregnancies with gestational age ≥22 weeks [13].
Based on these estimates the target sample size was set
at 1800, which was expected to provide sufficient power
for the outcome measures of low birth weight and pre-
term delivery, taking into account that some laboratory
results might not be linkable to the PRN.
Statistical analysis
Differences in frequency of pregnancy and delivery fea-
tures between the women with positive and negative serol-
ogy were analyzed in contingency tables with the c2t e s t .
Probability values <0.05 were considered statistically
significant. For each outcome, the strength of its associa-
tion with positive serology was expressed as a crude odds
ratio (OR) with 95% confidence interval (CI). We then
adjusted the ORs in a multivariable logistic regression ana-
lysis for potential confounders, to show the contribution of
the examined feature in relation to the other characteris-
tics. Interaction effects were also examined for each
confounder variable and serological status by using logistic
regression analysis. Missing values occurred for only 0.7%
of all confounders and were imputed once using R soft-
ware [14,15]. The other analyses were conducted using
software packages from SAS (version 9.1; SAS Institute,
Cary, NC, USA), SPSS (version 17.0; SPSS Inc. Chicago,
IL, USA), and Microsoft Excel.
Ethical considerations
The study was approved by the Medical Research Ethics
Committee of the University Medical Centre Utrecht
and the Board of the PRN. The latter included approval
obtained upon assessment by a privacy commission.
Results
Linkage
As the analysis was carried out using anonymized sam-
ples, without a unique personal identifier, the laboratory
results had to be linked to the 2007 and 2008 PRN data
by use of limited postal code information (4 digits) and
maternal date of birth. Of the 1739 sera samples col-
lected within the study period, 1678 were available for
linkage with PRN data (Figure 1). In the PRN database,
89702 deliveries were registered in the high incidence
area during 2007 and 2008. Within this total population,
3095 singleton deliveries were excluded based on the
indication that two or more had identical maternal date
of birth and four-digit postal code. Thus, these deliveries
belonged to different mothers and could not be validly
linked to the serological data. None of the multiple
deliveries with the same maternal date of birth and
four-digit postal code originated from different mothers,
as checked carefully by gestational age and number of
foetuses. Of the 1678 eligible sera, 1169 (70%) could be
linked to 1201 children registered in the PRN. For 25
children no neonatal outcome data were available and
in two cases there was no clear laboratory result, thus a
study population was generated composed of 1174 chil-
dren who originated from 1155 mothers.
Seroprevalence
The large majority (1646, 96%) of the 1713 sera that
were available had been obtained from women living in
10 adjacent municipalities in the high incidence area.
Based on the registered number of births in 2007, we
estimated that during the study period 60% of pregnant
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study (Table 1). Of the 1646 sera, 40 had an IgM II and
IgG II ≥1:64, of which four exhibited very intense fluor-
escence at the 1:64 dilution. In combination with the 16
sera with an IgM II ≥1:64 this gives an overall seropre-
valence of 3.40%. Nineteen (1.15%) sera had anti-phase I
and II IgG antibodies with a titre of ≥1:64 and without
IgM being present (Table 1). For the linked mothers,
the seroprevalence was found to be slightly lower, with
3.15% for possible recent infection (37 women, of whom
11 had solitary IgM II ≥1:64) and 1.02% for past infec-
tion. There was a clear correlation (Pearson correlation
coefficient = 0.707) between seroprevalence among
pregnant women and the incidence of notified sympto-
matic Q fever in the same municipalities. In addition to
the 19 sera with anti-phase I and II IgG antibodies,
t h e r ew e r e1 3 0s e r aw i t has o l i t a r yI g GI I≥1:64. Out of
the 1646 samples examined, 16 had an IgM I ≥1:64 and
30 had an IgG I ≥1:64. Although positive samples were
not fully titrated, none of the IgG I positive sera exhib-
ited intense fluorescence at the 1:64 dilution, making it
unlikely that the titres would be very high and suspect
for chronic Q fever.
Pregnancy outcome
Average age at delivery was 30.8 years (standard devia-
tion [SD] 4.2) for mothers with positive serology, and
30.5 (SD 4.5) for mothers with negative serology. The
other characteristics of mothers and infants are shown
i nT a b l e2 .T h e r ew a sac l e a rd i f f e r e n c ei no v e r a l l
seroprevalence by ethnic background (Dutch 2.6% vs
non-Dutch 9.2%; P = 0.006). This difference was less
pronounced when only positivity for anti-phase II IgM
and anti-phase II IgG antibodies was considered (Dutch
2.9% vs non-Dutch 5.5%; P = 0.143). Babies from
mothers with anti-phase II IgM and anti-phase II IgG
antibodies were more often born in a non-vertex posi-
tion, when only babies born after at least 37 weeks of
gestation were considered (P = 0.012). For other charac-
teristics of mothers and infants no statistically signifi-
cant differences were observed between the groups with
positive and negative serology.
Sera collected within the 
study period, N=1739 
Exclusion of sera with identical 
maternal dates of birth and 4 digit 
postal codes, which originated 
from different mothers, N=35 
Exclusion of double/triple sera 
per woman, collected within one 
year (only the last serum was 
retained for study), N= 26  
Sera available for linking 
with PRN, N=1678 
Deliveries from women living 
in the high incidence area, 
N=89,702
Exclusion of singleton deliveries with 
2 identical maternal dates of birth 
and 4 digit postal codes, N=3095 
Exclusion of deliveries outside the 
high incidence area, N= 291,719 
Deliveries available for linking 
with JBZ sera, N=86,625 
Linked deliveries,  
N=1201 
Final study population,
N=1174 
Exclusion of deliveries with 
missing data for neonatal 
outcome, N=25
Exclusion of sera lacking clear 
laboratory result, N=2 
One serum per mother 
within the study period, 
N=1713
Jeroen Bosch Hospital (JBZ)  The Netherlands Perinatal Registry (PRN) 
Deliveries in the Netherlands 
in 2007 and 2008, N=390,421
Figure 1 Flowchart of serological analyses and pregnancy outcome.
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positive serology was 3311 g (SD 637), while mothers
with negative serology produced babies of 3354 g (SD
678). Presence of antibodies against C. burnetii was not
significantly associated with any of the negative preg-
nancy outcome measures; the same was true when con-
sidering any adverse pregnancy outcome instead of each
outcome separately (Table 3). Adjustment for confoun-
ders in multiple logistic regression analyses did not
change the results (Table 4).
Discussion
In our study population, presence of antibodies against
C. burnetii in early pregnancy was not significantly asso-
ciated with adverse pregnancy outcome. This is in con-
trast with published case reports and case series that
suggest a high risk for adverse pregnancy outcome after
an acute symptomatic or asymptomatic Q fever infec-
tion in pregnancy [4,16-18].
Any explanation for this discrepancy, such as possible
differences in pathogenicity of different bacterial strains,
is speculative as long as there are no data available.
Reports from the literature on Q fever infection and
pregnancy outcome have been limited by the fact that
they have been based on small, selected numbers of
pregnant women. However, the present study also has a
number of limitations. The power of this study was
negatively affected by the lower than expected seropre-
v a l e n c ea n dt h er e l a t i v e l yl a r g en u m b e ro fw o m e nf o r
whom a serum sample was available but ultimately
could not be linked to the corresponding information in
t h eP R Nd a t a b a s e .W ew e r eu n a b l et od e t e r m i n et h e
reason for record linkage failure in most of those cases.
We made use of 12
th week sera, but only pregnancies
with a gestational age ≥16 weeks were registered in the
PRN; therefore, pregnancies ending between 12 and
16 weeks would have been missed. Thus, we cannot
exclude the possibility that mothers with positive serol-
ogy had higher rates of spontaneous abortion than did
the mothers with negative serology. It is interesting to
note, however, that antibodies suggesting recent infec-
tion were present in 4.0% of sera that were unable to be
linked to the PRN, in contrast to 3.2% in sera that were
able to be linked; this difference was not statistically sig-
nificant (P = 0.376). The PRN registry contains no data
on early pregnancy loss and spontaneous abortion, mak-
ing this outcome measure unfeasible. During the study
period, materials from 40 spontaneous abortions were
investigated at the Jeroen Bosch Hospital but none of
these materials was positive with PCR for C. burnetii
(unpublished data).
It has been suggested that complications from acute Q
fever occur more often when the infection takes place in
early pregnancy [7]. However, there is a paucity of infor-
mation on risks by trimester of infection. We were
unable to provide data on women who might have sero-
converted later (>12 weeks) in pregnancy. As no routine
serum samples were available from late pregnancy, these
data would be difficult to obtain and procuring such
samples would present considerable logistical challenges,
increased cost, ethical implications, and possible poor
compliance of subjects. Some important risk factors for
adverse pregnancy outcome, such as smoking during
pregnancy, could not be taken into account. Heavy
smoking during pregnancy is an item in the PRN, but
has a low prevalence and is considered to be largely
underreported. We had no information on occurrence
of other prenatal infections, such as syphilis, Listeria,
and group B streptococci, which are known to affect
pregnancy outcome.
Table 1 Presence of antibodies against Coxiella burnetii among pregnant women in 10 municipalities within the
province of Noord Brabant, the Netherlands, from June 2007 to July 2008
Municipality Pregnant women
tested
IgG I and IgG II
≥1:64 (%)
IgM II and IgG II ≥1:64
or IgM II ≥1:64 (%)
Births in
2007
1
Q fever incidence
in 2008
2
Oss 579 7 (1.2) 21 (3.6) 779 175
Uden 306 6 (2.0) 8 (2.6) 458 234
Veghel 293 3 (1.0) 5 (1.7) 377 38
Bernheze 240 1 (0.4) 15 (6.3) 326 344
Boekel 70 1 (1.4) 0 (0.0) 127 10
Landerd 60 0 (0.0) 4 (6.7) 122 791
Lith 37 0 (0.0) 3 (8.1) 57 342
Maasdonk 31 1 (3.2) 0 (0.0) 107 337
Sint-Oedenrode 15 0 (0.0) 0 (0.0) 151 23
Schijndel 15 0 (0.0) 0 (0.0) 219 17
Total 1646 19 (1.1) 56 (3.4) 2723 200
1 Total number of births that were registered in each municipality in the year 2007.
2Number of notified Q fever patients in the municipality from January 2008 to August 2008 per 100000 inhabitants (based on population size of the municipality
on 1 January 2008).
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cut-off titres that should be used for population-based
surveys in which only single titres are available; thus, it
is difficult to compare results between different studies
[19,20]. The largest study in the literature among preg-
nant women was carried out in south-eastern France, in
which 12716 pregnant women were tested at the end of
the pregnancy using an in-house developed IFA [21].
This study found a seroprevalence of 0.15% based on
IgG II ≥1:100. Moreover, high prevalence areas had the
highest proportion of preterm births, but the serological
results could not be linked to pregnancy outcome at the
individual level. In our study, 11 of the samples had an
isolated IgM ≥1:64 against phase II. The other 26 sam-
ples had an IgM and IgG against phase II, both ≥1:64.
A positive IgM against phase II has long been consid-
ered useful for the diagnosis of acute Q fever [22]. How-
ever, it has also been argued that an isolated positive
IgM against phase II could be the result of an aspecific
reaction. According to the manufacturer of Q fever IFA
IgM, the diagnosis of recent C. burnetii infection
requires a titre ≥1:16 for both phase I and phase II anti-
gens (package inserts; Focus Diagnostics; 2009, http://
www.focusdx.com/focus/packageInsert/IF0200M.pdf).
Tissot Dupont showed that a combination of a phase II
IgM titre ≥1:50 and phase II IgG titre ≥1:200 was 100%
predictive for active Q fever [23]. It has been argued
that local cut-off values need to be established, and for
Denmark, a low prevalence country, a cut-off for the
IgM phase II Focus Diagnostics IFA of ≥1:256 was
Table 2 Characteristics of mothers and infants and interpretation of serology for Coxiella burnetii
Characteristic IgG I and IgG II
≥1:64 (n = 12)
IgM II and IgG II ≥1:64
or IgM II ≥1:64 (n = 37)
No antibodies present
(n = 1125)
c2 test
1
n (%) n (%) n (%) P-value
Mothers
Parity
Primiparae 4 (33.3%) 19 (51.3%) 545 (48.4%)
Multiparae 8 (66.7%) 18 (48.7%) 580 (51.6%) 0.836
Ethnicity
Dutch 8 (66.7%) 31 (83.8%) 1021 (91.2%)
Other 4 (33.3%) 6 (16.2%) 99 (8.8%) 0.006
Missing 0 0 5
Socio-economic status
Very high 0 (0%) 4 (10.8%) 134 (12.0%)
High 1 (8.3%) 8 (21.6%) 171 (15.3%)
Average 7 (58.3%) 17 (46.0%) 546 (48.7%)
Low 3 (25.0%) 7 (18.9%) 199 (17.8%)
Very low 1 (8.3%) 1 (2.7%) 71 (6.3%) 0.838
Missing 0 0 4
Urbanization (addresses per km
2)
>1500 1 (8.3%) 6 (16.2%) 232 (20.7%)
500-1500 6 (50.0%) 16 (43.2%) 481 (42.9%)
<500 5 (41.7%) 15 (40.5%) 408 (36.4%) 0.538
Missing 0 0 4
Infants
Gender
Male 6 (50.0%) 21 (56.8%) 553 (50.3%)
Female 6 (50.0%) 16 (43.2%) 547 (49.7%) 0.508
Missing 0 0 25
Position
Vertex 12 (100%) 31 (83.8%) 1024 (93.4%)
Breech or other 0 (0%) 6 (16.2%) 73 (6.6%) 0.131
Missing 0 0 28
Plurality
Singletons 12 (100%) 36 (97.3%) 1076 (95.6%)
Multiples 0 (0%) 1 (2.7%) 49 (4.4%) 0.432
1Test for difference between antibodies present (columns 2 and 3) and absent (column 4).
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lands the prevalence of C. burnetii antibodies will be
higher than those in Denmark and, therefore, the posi-
tive predictive value of a serological test will be higher
at a lower cut-off. Furthermore, the choice of cut-off
point, when there are no definite rules, must also
depend on the reason for performing the test. In a
screening programme a high cut-off would result in very
few women with aspecific reactions being labelled as
false positive. However, a number of women with recent
infection but relatively low antibody titres would be
missed. The cut-off chosen for the present study was a
compromise between sensitivity and specificity of the
screening test. In the context of the ongoing discussions
Table 3 Pregnancy outcome by presence or absence of antibodies against Coxiella burnetii
Outcome IgG I and IgG II
≥1:64 (n = 12)
IgM II and IgG II
≥1:64 or IgM II ≥1:64 (n = 37)
No antibodies present
(n = 1125)
c2 test
1
n (%) n (%) n (%) P-value
Perinatal mortality
No 12 (100%) 37 (100%) 1101 (97.9%)
Yes 0 (0%) 0 (0%) 24 (2.1%) 0.151
Apgar score
<7 0 (0%) 1 (2.7%) 22 (2.0%)
≥7 12 (100%) 36 (97.3%) 1079 (98.0%) 0.983
Missing 0 0 24
Birth weight
<2500 g 2 (16.7%) 3 (8.1%) 86 (7.8%)
≥2500 g 10 (83.3%) 34 (91.9%) 1015 (92.2%) 0.544
Missing 0 0 24
Birth weight by gestational age (<p10)
No 9 (75.0%) 35 (94.6%) 969 (89.0%)
Yes 3 (25.0%) 2 (5.4%) 120 (11.0%) 0.858
Missing 0 0 36
Congenital malformations
No 12 (100%) 37 (100%) 1105 (98.2%)
Yes 0 (0%) 0 (0%) 20 (1.8%) 0.346
Gestational age
<37 weeks 1 (8.3%) 2 (5.4%) 109 (10.0%)
≥37 weeks 11 (91.7%) 35 (94.6%) 987 (90.1%) 0.378
Missing 0 0 29
Any adverse outcome
2
No 8 (66.7%) 32 (86.5%) 854 (75.9%)
Yes 4 (33.3%) 5 (13.5%) 271 (24.1%) 0.358
1Test for differences between antibodies present (columns 2 and 3) and absent (column 4).
2Any adverse outcome: perinatal death, birth weight <2500 g, birth weight by gestational age <p10, Apgar score <7, or gestational age <37 weeks.
Table 4 Multivariate analysis of seropositivity to Coxiella burnetii in relation to different adverse pregnancy outcomes
Outcome IgM II and IgG II ≥1:64
or IgM II ≥1:64
1
IgM II and IgG II ≥1:64
or IgM II ≥1:64
or IgG I and IgG II ≥1:64
2
Adjusted OR
3 (95% CI) Adjusted OR
3 (95% CI)
Gestational age <37 weeks 0.7 (0.2-2.2) 0.9 (0.3-2.3)
Birth weight <2500 g 1.2 (0.4-3.4) 1.6 (0.6-3.9)
Birth weight by gestational age (<p10) 0.4 (0.1-1.8) 0.9 (0.3-2.3)
Apgar score <7 1.7 (0.4-8.2) 1.3 (0.3-5.6)
Any adverse outcome
4 0.4 (0.2-1.2) 0.7 (0.3-1.5)
1 Reference category: no antibodies present, and IgG I and IgG II ≥1:64 combined.
2Reference category: no antibodies present.
3OR was adjusted for maternal age, parity, plurality, ethnic background, socio-economic status, urbanization, and foetal position.
4Any adverse outcome: perinatal death, birth weight <2500 g, birth weight by gestational age <p10, Apgar score <7, or gestational age <37 weeks.
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‘presence of anti-phase II IgM and anti-phase II IgG
antibodies’ rather than the term ‘recent infection’ in the
present study.
IgM phase II antibodies appear early in the disease
and decrease quickly between weeks 10 and 15 [22,23].
The IgM response, however, may persist for a longer
period of time and it is possible that women with a
positive serology were infected just before pregnancy,
which is probably less harmful than infection that
occurs in early pregnancy.
The prevalence of anti-phase II IgM and anti-phase II
IgG antibodies among pregnant women in this high
incidence area is lower than expected. However, the
study was carried out using samples obtained in 2007
and 2008, before the high incidence peak of Q fever
in 2009. The relatively high seroprevalence among
pregnant women with a non-Dutch ethnical background
is consistent with findings from a nationwide seropreva-
lence study among the general population. A higher
prevalence of past infection among people with a non-
Dutch ethnical background was found, especially for
individuals from Turkey [25].
The pathogenesis of adverse pregnancy outcome
caused by C. burnetii infection is not fully understood.
Infection of the placenta, placental insufficiency caused
by immunological mechanisms, and direct effects on the
foetus may all be contributing factors [4]. Similarly, the
effects of acute Q fever during pregnancy on the new-
born are unclear. In an endemic area in Egypt, 4 out of
100 cord sera obtained from normal newborns had high
levels of IgM specific for C. burnetii [26]. In contrast,
no evidence of foetal infection was found and cord
blood taken at delivery was negative for IgM antibodies
against C. burnetii in other case studies [27].
The large outbreaks of Q fever in the Netherlands
have resulted in high awareness among patients and
medical professionals. Laboratory tests are now widely
available, including PCR-based tests that can provide an
early diagnosis in the first two weeks of illness [28]. The
ability for laboratory diagnosis of Q fever was much fas-
ter in 2008 and 2009, as compared to 2007 [29]. It can,
therefore, be expected that most cases of symptomatic
Q fever during pregnancy in the high incidence area will
be detected and treated. Asymptomatic infections can
only be identified by screening. Unfortunately, the pre-
sent study cannot provide a clear answer to whether or
not a large-scale screening program would provide ben-
efits in terms of preventing adverse pregnancy outcomes
and infection from occupational exposure.
Conclusion
In conclusion, we found no evidence for adverse effects
on pregnancy outcome among pregnant women with
asymptomatic presence of anti-phase II IgM and anti-
phase II IgG antibodies in early pregnancy. The present
study provides insufficient basis for recommending large
scale screening of pregnant women in high incidence
areas. With the expanding Q fever problem, there
remains an urgent need for a more definitive answer,
a n dw ea n t i c i p a t et h a tt h i sw i l lb ep r o v i d e db yt h e
large-scale prospective screening and treatment study
which was initiated in March 2010. That on-going study
is entitled “cost-effectiveness of a screening strategy for
Q fever among pregnant women in risk areas: a clus-
tered randomized controlled trial” and aims to include
4000 participants [30].
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